Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.

By Cory Renauer - Mar 6, 2017 at 9:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Several of the most interesting drugs in development belong to Bellicum and bluebird bio, but which is the better stock pick right now?

Bellicum Pharmaceuticals Inc. (BLCM -4.13%) and bluebird bio Inc. (BLUE -3.07%) occupy an interesting corner of the biotech industry. Both clinical-stage biotechs are developing cellular therapies for the treatment of blood disorders and cancer.

Neither has an approved product to sell, although candidates winding their way through development stages could generate billions. Let's see how the potential new therapies they have in development measure up to see which of these stocks is the better pick at the moment.

Two people with light bulbs for heads pulling on two sides of a balance scale.

Image source: Getty Images.

Bellicum Pharmaceuticals Inc.: Under control

Bellicum's lead candidate, BPX-501, is a novel solution to a common problem. Stem-cell transplants can effectively treat a range of blood-based diseases, but using donor cells from a less-than-perfect match is so dangerous that the procedure is severely limited.

The most lethal complication that arises when transplanting stem cells from less than perfectly matched donors is graft-versus-host disease (GVHD), an immune-system attack on donor stem cells. Recipients typically undergo immune-cell depletion ahead of transplants to avoid GVHD, which presents complications of its own.

Bellicum's candidate involves modifying donor immune cells with a kill switch that healthcare providers can activate with simple administration of rimiducid. In an ongoing trial with 122 pediatric patients receiving partially matched donor stem-cell transplants, five cases of uncontrolled GVHD were resolved by activating the shut-off switch.

Bellicum has also begun human trials with BPX-601 for the treatment of inoperable pancreatic cancer, a disease with tremendous unmet need. The candidate involves modifying immune cells to attack tumors expressing a specific target on their surfaces. There are a handful of biotechs advancing chimeric antigen receptor modified T-cells (CAR-T) through clinical trials, but BPX-601 has a unique safety switch similar to BPX-501.

Three laboratory technicians at work

Image source: Getty Images.

Bellicum's controllable CAR-T technology could become all the rage. These experimental therapies have shown an ability to help patients who had failed numerous lines of treatment with existing drugs. However, some have proven too effective. Rapid cancer-cell destruction has been linked to severe, sometimes fatal, side effects.

bluebird bio Inc.: Another approach

bluebird bio's lead candidate could eventually compete with Bellicum's for patients with transfusion-dependent beta-thalassemia and severe sickle disease, two inherited disorders caused by faulty hemoglobin genes. Bluebird's LentiGlobin involves reintroducing a patient's own stem cells after they've been modified to produce functional hemoglobin. Perfectly matched stem cells present very little risk of GVHD, which could render Bellicum's lead candidate redundant.

If approved, annual LentiGlobin sales could eventually peak at around $1 billion for the treatment of beta-thalassemia and $3 billion in the larger sickle-cell indication. That makes it the company's most important clinical-stage asset, but it's not the only one with nine-figure annual sales potential.

Bluebird also boasts a CAR-T candidate for the treatment of multiple myeloma called bb2121 that could go on to generate about $3.6 billion in annual sales at its peak. Last December, Bluebird presented interim data from a small trial with patients who had relapsed following between five and 13 previous lines of treatment. Despite being so heavily pretreated, seven of nine evaluable patients' disease showed a response.

About a year ago, Celgene exercised an option to develop and possibly commercialize bb2121, and remarkable data suggests the big biotech made a smart decision. The agreement removes a great deal of risk for Bluebird while leaving it eligible for hefty milestone and royalty payments if it succeeds.

The better buy

LentiGlobin and BPX-501 are deep in uncharted waters, and CAR-T therapies are still experimental across the board. While the combination of safety and efficacy we've seen so far is highly encouraging, investors in either company need to brace themselves for regulatory uncertainty.

Should any or all of these biotechs' candidates earn approvals, their commercial viability is another big question mark. Cellular-based therapies present enormous challenges for patients and healthcare providers that you just don't see with simple pills or injections.

With a market cap of about $3.35 billion, Bluebird stock has a long way to fall if it runs into any surprise potholes on the way to Profit Town. Should disaster strike, Bellicum has a much lower perch to fall from, with a recent market cap of just $326 million.

In fact, the smaller company's stock is so cheap that I think it underestimates the safety switch technology's long-term potential and makes the company a potential acquisition target. Add it all up, and Bellicum Pharmaceuticals looks the better buy right now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bellicum Pharmaceuticals, Inc. Stock Quote
Bellicum Pharmaceuticals, Inc.
BLCM
$1.16 (-4.13%) $0.05
bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$4.26 (-3.07%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.